Involvement of CD56brightCD11c+ cells in IL-18-mediated expansion of human γδ T cells

Journal of Immunology

Volumn 186, Issue 4, 2011, Pages 2003-2012

  Tsuda, Junko ^a,b   Li, Wen ^a,b   Yamanishi, Hiromichi ^b   Yamamoto, Hideyuki ^a   Okuda, Akico ^a   Kubo, Shuji ^a   Ma, Zhifeng ^a   Terada, Nobuyuki ^a   Tanaka, Yoshimasa ^c   Okamura, Haruki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Hirakataryoikuen   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 BUTEN 1 OL; 2 METHYL 3 BUTENYL 1 PYROPHOSPHATE; B7 ANTIGEN; CD14 ANTIGEN; CD18 ANTIGEN; CD56 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RECOMBINANT INTERLEUKIN 18; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; INTERLEUKIN 18; LYMPHOCYTE ANTIGEN RECEPTOR; NCAM1 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; CELL CULTURE; CELL EXPANSION; CELL PROLIFERATION; CELL STRAIN K 562; CYTOTOXICITY; DENDRITIC CELL; DRUG RESPONSE; GAMMA DELTA T LYMPHOCYTE; HUMAN; INTERFERON PRODUCTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ADULT; BIOSYNTHESIS; CELL CLONE; CELL DIFFERENTIATION; CYTOLOGY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; NATURAL KILLER CELL; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, CD11C; ANTIGENS, CD56; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CLONE CELLS; DENDRITIC CELLS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-18; K562 CELLS; KILLER CELLS, NATURAL; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS;

EID: 79951823671     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001919     Document Type: Article

References (50)

1. Bonneville, M., and E. Scotet. 2006. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 18: 539-546.
2. Moser, B., and M. Eberl. 2007. gammadelta T cells: novel initiators of adaptive immunity. Immunol. Rev. 215: 89-102.
3. Beetz, S., D. Wesch, L. Marischen, S. Welte, H. H. Oberg, and D. Kabelitz. 2008. Innate immune functions of human gammadelta T cells. Immunobiology 213: 173-182. (Pubitemid 351484782)
4. Caccamo, N., S. Meraviglia, F. Scarpa, C. La Mendola, D. Santini, C. T. Bonanno, G. Misiano, F. Dieli, and A. Salerno. 2008. Aminobisphosphonate- activated gammadelta T cells in immunotherapy of cancer: doubts no more. Expert Opin. Biol. Ther. 8: 875-883.
5. Thedrez, A., C. Sabourin, J. Gertner, M. C. Devilder, S. Allain-Maillet, J. J. Fournié, E. Scotet, and M. Bonneville. 2007. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol. Rev. 215: 123-135. (Pubitemid 46212235)
6. O'Brien, R. L., C. L. Roark, N. Jin, M. K. Aydintug, J. D. French, J. L. Chain, J. M. Wands, M. Johnston, and W. K. Born. 2007. gammadelta T-cell receptors: functional correlations. Immunol. Rev. 215: 77-88.
7. Chien, Y. H., and Y. Konigshofer. 2007. Antigen recognition by gammadelta T cells. Immunol. Rev. 215: 46-58.
8. Morita, C. T., C. Jin, G. Sarikonda, and H. Wang. 2007. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol. Rev. 215: 59-76.
9. Hayday, A. C. 2000. [γ][δ] cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18: 975-1026.
10. Hintz, M., A. Reichenberg, B. Altincicek, U. Bahr, R. M. Gschwind, A. K. Kollas, E. Beck, J. Wiesner, M. Eberl, and H. Jomaa. 2001. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Lett. 509: 317-322. (Pubitemid 34015963)
11. Tanaka, Y., C. T. Morita, Y. Tanaka, E. Nieves, M. B. Brenner, and B. R. Bloom. 1995. Natural and synthetic non-peptide antigens recognized by human γ δ T cells. Nature 375: 155-158.
12. Hayday, A. C. 2009. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 31: 184-196.
13. Gober, H. J., M. Kistowska, L. Angman, P. Jenö, L. Mori, and G. De Libero. 2003. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197: 163-168.
14. Miyagawa, F., Y. Tanaka, S. Yamashita, and N. Minato. 2001. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human γ δ T cells by aminobisphosphonate antigen. J. Immunol. 166: 5508-5514. (Pubitemid 32374172)
15. Roelofs, A. J., M. Jauhiainen, H. Mönkkönen, M. J. Rogers, J. Mönkkönen, and K. Thompson. 2009. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/ DMAPP. Br. J. Haematol. 144: 245-250.
16. Kato, Y., Y. Tanaka, H. Tanaka, S. Yamashita, and N. Minato. 2003. Requirement of species-specific interactions for the activation of human γ δ T cells by pamidronate. J. Immunol. 170: 3608-3613. (Pubitemid 36359229)
17. Morita, C. T., E. M. Beckman, J. F. Bukowski, Y. Tanaka, H. Band, B. R. Bloom, D. E. Golan, and M. B. Brenner. 1995. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human γ δ T cells. Immunity 3: 495-507.
18. Martino, A., and F. Poccia. 2007. γ δ T cells and dendritic cells: close partners and biological adjuvants for new therapies. Curr. Mol. Med. 7: 658-673.
19. Scotet, E., S. Nedellec, M. C. Devilder, S. Allain, and M. Bonneville. 2008. Bridging innate and adaptive immunity through gammadelta T-dendritic cell crosstalk. Front. Biosci. 13: 6872-6885.
20. Münz, C., R. M. Steinman, and S. Fujii. 2005. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J. Exp. Med. 202: 203-207.
21. Eberl, M., and B. Moser. 2009. Monocytes and gammadelta T cells: close encounters in microbial infection. Trends Immunol. 30: 562-568.
22. Jacobs, B., M. Wuttke, C. Papewalis, J. Seissler, and M. Schott. 2008. Dendritic cell subtypes and in vitro generation of dendritic cells. Horm. Metab. Res. 40: 99-107.
23. Conti, L., and S. Gessani. 2008. GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiology 213: 859-870.
24. Homann, D., A. Jahreis, T. Wolfe, A. Hughes, B. Coon, M. J. van Stipdonk, K. R. Prilliman, S. P. Schoenberger, and M. G. von Herrath. 2002. CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity 16: 403-415. (Pubitemid 34260918)
25. Pillarisetty, V. G., S. C. Katz, J. I. Bleier, A. B. Shah, and R. P. Dematteo. 2005. Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-g via autocrine IL-12. J. Immunol. 174: 2612-2618.
26. Chaudhry, U. I., T. P. Kingham, G. Plitas, S. C. Katz, J. R. Raab, and R. P. DeMatteo. 2006. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-g and inhibit tumor growth. Cancer Res. 66: 10497-10504.
27. Chaudhry, U. I., G. Plitas, B. M. Burt, T. P. Kingham, J. R. Raab, and R. P. DeMatteo. 2007. NK dendritic cells expanded in IL-15 exhibit antitumor responses in vivo. J. Immunol. 179: 4654-4660.
28. Chauvin, C., and R. Josien. 2008. Dendritic cells as killers: mechanistic aspects and potential roles. J. Immunol. 181: 11-16.
29. + NK helper cells. J. Exp. Med. 202: 941-953.
30. Vosshenrich, C. A. J., S. Lesjean-Pottier, M. Hasan, O. Richard-Le Goff, E. Corcuff, O. Mandelboim, and J. P. Di Santo. 2007. CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J. Exp. Med. 204: 2569-2578.
31. Son,Y. I., R.M.Dallal, R. B.Mailliard, S.Egawa, Z. L. Jonak, and M.T. Lotze. 2001. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells. Cancer Res. 61: 884-888. (Pubitemid 32174396)
32. Conti, L., M. Cardone, B. Varano, P. Puddu, F. Belardelli, and S. Gessani. 2008. Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. Eur. J. Immunol. 38: 750-762.
33. Milush, J. M., B. R. Long, J. E. Snyder-Cappione, A. J. Cappione, III, V. A. York, L. C. Ndhlovu, L. L. Lanier, J. Michaëlsson, and D. F. Nixon. 2009. Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood 114: 4823-4831.
34. Gruenbacher, G., H. Gander, A. Rahm, W. Nussbaumer, N. Romani, and M. Thurnher. 2009. CD56+ human blood dendritic cells effectively promote TH1-type gammadelta T-cell responses. Blood 114: 4422-4431.
35. Reschner, A., P. Hubert, P. Delvenne, J. Boniver, and N. Jacobs. 2008. Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response. Clin. Exp. Immunol. 152: 219-226.
36. c) family cytokines. Nat. Rev. Immunol. 9: 480-490.
37. Sutton, C. E., S. J. Lalor, C. M. Sweeney, C. F. Brereton, E. C. Lavelle, and K. H. Mills. 2009. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31: 331-341.
38. Traxlmayr, M. W., D. Wesch, A. M. Dohnal, P. Funovics, M. B. Fischer, D. Kabelitz, and T. Felzmann. 2010. Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells. J. Immunother. 33: 40-52.
39. Campos Alberto, E. J., N. Shimojo, M. Aoyagi, and Y. Kohno. 2009. Differential effects of tumour necrosis factor-α and interleukin-12 on isopentenyl pyrophosphate-stimulated interferon-γ production by cord blood Vgamma9 T cells. Immunology 127: 171-177.
40. Kang, N., L. Tang, X. Li, D. Wu, W. Li, X. Chen, L. Cui, D. Ba, and W. He. 2009. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human. Immunol. Lett. 125: 105-113.
41. Li, W., S. Kubo, A. Okuda, H. Yamamoto, H. Ueda, T. Tanaka, H. Nakamura, H. Yamanishi, N. Terada, and H. Okamura. 2010. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J. Immunother. 33: 287-296.
42. Okamura, H., H. Tsutsi, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88-91.
43. Nakanishi, K., T. Yoshimoto, H. Tsutsui, and H. Okamura. 2001. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 19: 423-474.
44. Dinarello, C. A. 2007. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol. 27: 98-114.
45. Chandrasekar, B., S. Mummidi, W. C. Claycomb, R. Mestril, and M. Nemer. 2005. Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J. Biol. Chem. 280: 4553-4567.
46. Hodge, D. L., J. J. Subleski, D. A. Reynolds, M. D. Buschman, W. B. Schill, M. W. Burkett, A. M. Malyguine, and H. A. Young. 2006. The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death. J. Interferon Cytokine Res. 26: 706-718.
47. Li, W., S. Kashiwamura, H. Ueda, A. Sekiyama, and H. Okamura. 2007. Protection of CD8+ T cells from activation-induced cell death by IL-18. J. Leukoc. Biol. 82: 142-151.
48. Majumdar, G., I. M. Johnson, S. Kale, and R. Raghow. 2008. Epigenetic regulation of cardiac muscle-specific genes in H9c2 cells by interleukin-18 and histone deacetylase inhibitor m-carboxycinnamic acid bis-hydroxamide. Mol. Cell. Biochem. 312: 47-60.
49. Tschopp, J., and K. Schroder. 2010. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat. Rev. Immunol. 10: 210-215.
50. Gnant, M., B. Mlineritsch, W. Schippinger, G. Luschin-Ebengreuth, S. Pöstlberger, C. Menzel, R. Jakesz, M. Seifert, M. Hubalek, V. Bjelic-Radisic, et al; ABCSG-12 Trial Investigators. 2009. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360: 679-691.